Liquidation: ESSA Pharma Inc.

Form Type: SCHEDULE 13D

Filing Date: 2025-04-15

Corporate Action: Liquidation

Type: Update

Accession Number: 000121390025032152

Filing Summary: On April 15, 2025, ESSA Pharma, Inc. was subject to a Schedule 13D filing by Soleus Capital entities, indicating a potential strategic shift. The filing replaces a previous Schedule 13G and is a response to the Reporting Persons' belief that they may no longer qualify for the simpler filing. The Reporting Persons, including Soleus Capital Master Fund, express their intention to engage with the Issuer's Board regarding enhancing shareholder value, which may include winding down operations and liquidating the Issuer to return cash to shareholders. They believe the current share price significantly undervalues the Issuer, being below its cash reserves on a per-share basis. The Reporting Persons currently hold approximately 5.1% of the outstanding shares of ESSA Pharma, Inc., totaling 2,262,026 shares. This letter sent to the Board outlines their investment motivations and potential actions concerning their holdings.

Document Link: View Document